HANSOH PHARMAC Financials
| 3KY Stock | EUR 2.16 0.06 2.70% |
HANSOH |
Understanding current and past HANSOH PHARMAC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HANSOH PHARMAC's financial statements are interrelated, with each one affecting the others. For example, an increase in HANSOH PHARMAC's assets may result in an increase in income on the income statement.
HANSOH PHARMAC Stock Summary
HANSOH PHARMAC competes with Merck, Takeda Pharmaceutical, Guangzhou Baiyunshan, and Elanco Animal. Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | KYG549581067 |
| Business Address | 9 Dongjin Road |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.hspharm.com |
| Phone | 86 21 3177 3517 |
| Currency | EUR - Euro |
You should never invest in HANSOH PHARMAC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of HANSOH Stock, because this is throwing your money away. Analyzing the key information contained in HANSOH PHARMAC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
HANSOH PHARMAC Key Financial Ratios
There are many critical financial ratios that HANSOH PHARMAC's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that HANSOH PHARMAC HD reports annually and quarterly.| Return On Equity | 0.14 | |||
| Return On Asset | 0.063 | |||
| Beta | 0.57 | |||
| Z Score | 73.8 | |||
| Last Dividend Paid | 0.12 |
HANSOH Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HANSOH PHARMAC's current stock value. Our valuation model uses many indicators to compare HANSOH PHARMAC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HANSOH PHARMAC competition to find correlations between indicators driving HANSOH PHARMAC's intrinsic value. More Info.HANSOH PHARMAC HD 00001 is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for HANSOH PHARMAC HD 00001 is roughly 2.17 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HANSOH PHARMAC's earnings, one of the primary drivers of an investment's value.HANSOH PHARMAC HD Systematic Risk
HANSOH PHARMAC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HANSOH PHARMAC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on HANSOH PHARMAC HD correlated with the market. If Beta is less than 0 HANSOH PHARMAC generally moves in the opposite direction as compared to the market. If HANSOH PHARMAC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HANSOH PHARMAC HD is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HANSOH PHARMAC is generally in the same direction as the market. If Beta > 1 HANSOH PHARMAC moves generally in the same direction as, but more than the movement of the benchmark.
HANSOH PHARMAC December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HANSOH PHARMAC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HANSOH PHARMAC HD 00001. We use our internally-developed statistical techniques to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on widely used predictive technical indicators. In general, we focus on analyzing HANSOH Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HANSOH PHARMAC's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.09 | |||
| Information Ratio | 0.0056 | |||
| Maximum Drawdown | 25.77 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 7.89 |
Complementary Tools for HANSOH Stock analysis
When running HANSOH PHARMAC's price analysis, check to measure HANSOH PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HANSOH PHARMAC is operating at the current time. Most of HANSOH PHARMAC's value examination focuses on studying past and present price action to predict the probability of HANSOH PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HANSOH PHARMAC's price. Additionally, you may evaluate how the addition of HANSOH PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |